- Home
- NCI vs RLMD Comparison
NCI vs RLMD Comparison
Compare NCI & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCI
- RLMD
- Stock Information
- Founded
- NCI 1992
- RLMD 2004
- Country
- NCI Hong Kong
- RLMD United States
- Employees
- NCI N/A
- RLMD N/A
- Industry
- NCI
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- NCI
- RLMD Health Care
- Exchange
- NCI NYSE
- RLMD Nasdaq
- Market Cap
- NCI 11.0M
- RLMD 11.5M
- IPO Year
- NCI 2024
- RLMD N/A
- Fundamental
- Price
- NCI $0.39
- RLMD $0.27
- Analyst Decision
- NCI
- RLMD Hold
- Analyst Count
- NCI 0
- RLMD 4
- Target Price
- NCI N/A
- RLMD $4.25
- AVG Volume (30 Days)
- NCI 436.7K
- RLMD 525.9K
- Earning Date
- NCI 12-19-2024
- RLMD 05-07-2025
- Dividend Yield
- NCI N/A
- RLMD N/A
- EPS Growth
- NCI N/A
- RLMD N/A
- EPS
- NCI 0.08
- RLMD N/A
- Revenue
- NCI $22,481,862.00
- RLMD N/A
- Revenue This Year
- NCI N/A
- RLMD N/A
- Revenue Next Year
- NCI N/A
- RLMD N/A
- P/E Ratio
- NCI $5.11
- RLMD N/A
- Revenue Growth
- NCI N/A
- RLMD N/A
- 52 Week Low
- NCI $0.35
- RLMD $0.24
- 52 Week High
- NCI $11.39
- RLMD $5.84
- Technical
- Relative Strength Index (RSI)
- NCI N/A
- RLMD 36.15
- Support Level
- NCI N/A
- RLMD $0.26
- Resistance Level
- NCI N/A
- RLMD $0.29
- Average True Range (ATR)
- NCI 0.00
- RLMD 0.02
- MACD
- NCI 0.00
- RLMD 0.01
- Stochastic Oscillator
- NCI 0.00
- RLMD 57.82
About NCI NEO-CONCEPT INTL GRP HLDGS LTD
Neo-Concept International Group Holdings Ltd is a company whose a one-stop apparel solution services provider. It offers a full suite of services in the apparel supply chain, including market trend analysis, product design and development, raw material sourcing, production and quality control, and logistics management serving customers located in the European, and North American markets through Neo-Concept HK.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.